Please assess the completion status of the following clinical trial:

Trial Title: The Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) Protocol

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Previous diagnosis of RA according to the revised 1987 criteria of the American Rheumatism Association (Arnett et al., 1988)~* patients must have a minimum of 8 tender and 4 swollen joints with disease diagnosed at least 3 months prior to screening~* patients must have been using oral or parenteral MTX for at least the previous 3 months, and at a stable dose of 7.5 to 25 mg per week for at least the previous 1 month~* women of childbearing potential must test negative for pregnancy and be using adequate birth control measures~* patients must have a documented purified protein derivative (PPD) skin test performed at prescreening.~Exclusion Criteria:~* Patients who have received any prior treatment with infliximab or with any other therapeutic agent targeted at reducing tumor necrosis factor (TNF) (e.g., etanercept, pentoxifylline or thalidomide) within the previous 3 months~* patients who are incapacitated~* history of infected joint prosthesis within the previous 5 years~* patients with a concomitant diagnosis of congestive heart failure (CHF), history of or known malignancy within the previous 5 years, cases of active or latent tuberculosis (TB), acute or chronic serious infections within the past 3 months~* known substance abuse (drug or alcohol) within the previous 3 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).